- Evenement
- Bron: Campus Sanofi
- 3 sep 2025
PulmoRounds 2025

The PulmoRounds 2025 are coming to the Netherlands. The PulmoRounds is a series of educational events taking place across Scandinavia and the Benelux countries. The events bring together physicians treating severe asthma and COPD patients. It entails scientific exchange and discussion on clinical challenges with two international key opinion leaders in the respiratory field.
The educational programme focuses on:
- Asthma: Decoding the natural history of the disease, including mucus plugging and airway remodeling and addressing key pressure points in clinical management of severe asthma today.
- COPD: Exploring inflammation, biomarkers, and eosinophil (EOS) measurements to optimize precision treatment using biologics.
The initiative aligns with the growing demand for expert-led, real-world guidance to improve patient outcomes in chronic respiratory diseases. The PulmoRounds aim to empower healthcare providers with actionable insights to enhance patient care.
The educational programme brings expert knowledge directly to healthcare providers through a structured and well-demonstrated setup. This includes:
- Interactive lectures tailored to local clinical practice.
- Case discussion to bridge theory and practice.
This event is organised by Sanofi-Regeneron. All hospitality provided is fully compliant with CGR guidelines.
Save the date

Date: Wednesday the 3rd of December 2025

Time: 18.00 CET

Location: On-site from
PAUSHUIZE
Kromme Nieuwegracht 49, Utrecht
Programme
18.00 - 18.20 |
Welcome and IntroductionType II Inflammatory Diseases (Asthma & COPD) By Dr. Hans in't Veen (NL) |
18.20 – 19.00 |
Breathing New Life into COPDUnderstanding Inflammation Types, Biomarkers, EOS Measurement, and the Role of Biologics in COPD By Prof. Dr. Dave Singh (UK) |
19.00 – 19.15 |
Break |
19.15 – 19.55 |
Asthma UnpluggedExploring Mucus Plugging, Airway Remodeling in Asthma and Insights from Real-World Data By Prof. Dr. Alberto Papi (IT) |
19.55 - 20.25 |
Q&A and panel discussionBy Dr. Hans in 't Veen (NL), Prof. Dave Singh (UK), and Prof. Alberto Papi (IT) |
International speakers

Dr. Hans in't Veen
Researcher at Franciscus Gasthuis & Vlietland, NL

Prof. Dave Singh
Professor of Clinical Pharmacology and Respiratory Medicine at the University of Manchester, UK

Prof. Dr. Alberto Papi
Professor of Respiratory Medicine at the University of Ferrara,
Italy
Alberto Papi is Professor of Respiratory Medicine at the University of Ferrara, Italy, and Director of the Respiratory Unit of the Department of CardioThoracic Medicine, S. Anna University Hospital, Ferrara, Italy.
Professor Papi trained in Respiratory Medicine at the University of Parma, and spent 4 years in the UK as a Clinical Research Fellow at the University of Southampton, where he is an Honorary Clinical Lecturer. In 2015, he was made a Fellow of the European Respiratory Society. He is Member of the GOLD Science Committee.
Professor Papi’s principal field of research is airway inflammation in asthma and COPD, its molecular mechanisms and pharmacological modulation. In his studies, he has taken particular interest in the role of respiratory viral infections in stable/exacerbated obstructive lung diseases, and the underlying molecular and immunological mechanisms. He has coordinated several studies, particularly in asthma and COPD, and he has given presentations at national and international meetings. He has published more than 600 articles in peer-reviewed journals (including NEJM, Lancet, Lancet Respiratory Medicine, AJRCCM), and several other publications in non-peer-reviewed journals. H Index 103.
After graduating in Medicine from Cambridge University, I trained in respiratory medicine and clinical pharmacology. This included an industrial placement for phase 1 experience. I completed an MD at the University of Manchester, and then was appointed as senior lecturer in respiratory pharmacology based in the University Hospital of South Manchester in 2003. My research interests are the pharmacotherapy of Asthma and COPD with studies spanning from basic pharmacology investigations of anti-inflammatory drug action to clinical trials. I am medical director of the Medicines Evaluation Unit performing proof of concept studies in obstructive lung diseases.
Neem contact op

Sanofi, MAT-BE-2500695, 06/2025